¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inhibition test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
¿µ¹® visual field test ÇÑ±Û ½Ã¾ß°Ë»ç
¼³¸í   
  ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ Ã¤, °üÂûÇÒ ¼ö Àִ ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇϴ °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃ߾¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤Çϴ °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼­ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, À̿ܠ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ.
¿µ¹® Draw a person test ÇÑ±Û Àι°È­ ¼º°Ý°Ë»ç
¼³¸í   
  Àι°È­ ¼º°Ý°Ë»ç´Â Ã³À½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ Àִ ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀڴ ±×¸®´Â ¼ø¼­¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼­ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇѴٴ ÀÔÀå, ±×¸²¿¡¼­ °­Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ­, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼭µµ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È­¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù.
¿µ¹® intelligence test ÇÑ±Û Áö´É°Ë»ç
¼³¸í   
  1905³â ÇÁ¶û½ºÀÇ ºñ³×°¡ Á¤½Å¹Ú¾à¾Æ¸¦ ÀϹݾƵ¿À¸·ÎºÎÅÍ ÆÇº°Çϱâ À§ÇÏ¿© ÀÛ¼ºÇÑ °ÍÀÌ Áö´É°Ë»çÀÇ ½ÃÀÛÀÌ´Ù. Áö´É°Ë»ç´Â ±×ÀÇ ¸ñÀûÀ¸·ÎºÎÅÍ ÀϹÝÀû Áö´É°Ë»ç¿Í Áø´Ü¿ë Áö´É°Ë»ç·Î ³ª´²Áö°í, ½Ç½Ã¹æ¹ý¿¡¼­ °³Àοë(°³º°½Ä)°ú Áý´Ü¿ë(´Üü½Ä)À¸·Î ºÐ·ùµÇ°í ¶Ç ¹®Á¦ÀÇ ³»¿ëÀ¸·ÎºÎÅÍ ¾ð¾î¼º°Ë»ç(A½Ä ¶Ç´Â ¥á½Ä)¿Í ºñ¾ð¾î¼º°Ë»ç(B½Ä ¥â½Ä)·Î ³ª´²Áø´Ù. Áö´É°Ë»çÀÇ °á°úÀǠǥ½Ã¹ýÀº Á¤½Å¿¬·É(mental age, MA), Áö´ÉÁö¼ö(intelligence quotient, IQ), Áö´ÉÆíÂ÷Ä¡(intelligence standard score, ISS)µîÀÌ ÀÖ´Ù. Áö´É°Ë»ç¿¡´Â ¿ª»çÀûÀ¸·Î ºñ³×½Ä°ú À°±º½ÄÀÇ µÎ °èÅëÀÌ ÀÖ´Ù. ºñ³×½ÄÀº °Ë»çÀÚ°¡ °³º°ÀûÀ¸·Î ÇÑ °³ ¹®Ç×¾¿ Áú¹®À» Çϸé ÀÌ¿¡ ´ëÇÏ¿© Çǰ˻çÀÚ°¡ ¸»À̳ª ÇൿÀ¸·Î ÀÀ´äÇϴ ¹æ¹ý(°³º°½Ä-¹®´ä½Ä)À̰í, À°±º½ÄÀº ÀϹÝÀûÀΠ¹æ½ÄÀ¸·Î´Â ÀμâµÈ ¹®Á¦¿ëÁö¸¦ »ç¿ëÇÏ¿© Çǰ˻çÀÚ°¡ ¼ÒÁ¤ÀÇ ½Ã°£ ³»¿¡ µÇµµ·Ï ¸¹ÀÌ ¹Ù¸£°Ô(½Ã°£Á¦Çѹý) È¸´äÀ» ±âÀÔÇÑ´Ù(Çʱâ¹ý). Çѱ¹ ÃÖÃÊÀÇ Áö´É°Ë»ç´Â 1954³â ¼­¿ï´ëÇб³ »ç¹ü´ëÇР±³À°½É¸®¿¬±¸½Ç¿¡¼­ Á¦ÀÛÇÑ °£Æí Áö´É°Ë»çÀÌ´Ù. °£Æí Áö´É°Ë»ç ÀÌÈÄ ´Ù¼öÀÇ Áý´Ü Áö´É°Ë»ç°¡ ÃâÇöÇÏ¿´´Âµ¥ ºñ±³Àû ÃÖ±Ù¿¡ Ç¥ÁØÈ­µÈ Áö´É°Ë»ç·Î´Â Çѱ¹Çൿ°úÇבּ¸¼Ò°¡ 1984³â¿¡ Àü±¹ °íµîÇб³ ÇлýÀ» ´ë»óÀ¸·Î Á¦ÀÛÇÑ KIT-S Áö´É°Ë»ç°¡ ÀÖ´Ù.
¿µ¹® patch test ÇÑ±Û Ã¸Æ÷°Ë»ç
¼³¸í   
  ÇǺξ˷¹¸£±â¿¡ ´ëÇÑ °Ë»ç¹æ¹ýÀ¸·Î Ç׿øÀ» ºÙÀΠøÆ÷¸¦ ÇǺο¡ ºÎÂøÇÑ ´ÙÀ½ 2ÀÏ ÈÄ¿¡ »çÇϰí, ´Ù½Ã 2ÀÏ ÈÄ¿¡ °Ë»çÇÑ´Ù. 2¹ø ¸ðµÎ ÇǺÎÀÌ»óÀÌ ³ªÅ¸³ª¸é, ¾Ë·¹¸£±â¹ÝÀÀ¿¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀ̸ç, ¸¸¾à Ã³À½ 2ÀÏ¿¡´Â ÀÌ»óÀÌ ÀÖÁö¸¸, ´ÙÀ½ 2ÀÏ ÈÄ °Ë»ç¿¡¼­ ÀÌ»ó¼Ò°ßÀÌ ¾øÀ¸¸é, ±×°ÍÀº ´ÜÁö ÇǺÎÀڱؿ¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀÏ »ÓÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • migration inhibition factor
    À̵¿ÀúÁöÀÎÀÚ
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ½Ã³À½ºÀÌÈľïÁ¦, ¿¬Á¢ÀÌÈľïÁ¦
  • presynaptic inhibition
    ½Ã³À½ºÀÌÀü¾ïÁ¦, ¿¬Á¢ÀÌÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý, »ó¹Ý¾ïÁ¦Á¤½Å¿ä¹ý
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
  • selective inhibition
    ¼±ÅþïÁ¦
  • acceptance test
    Àμö°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blood sugar test
    Ç÷´ç°Ë»ç
  • bronchial provocation test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs' test
    (¢¡antiglobulin test) ÄñÁî°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • D-xylose test
    Å©½Ç·Î¿À½º°Ë»ç
  • dip-stick test
    ¿ä½ÃÇèÁö°Ë»ç
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • flashlight swinging test
    ±³´ëºÒºû°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • guaiac test
    ÀáÇ÷°Ë»ç
  • Ham's test
    Çܰ˻ç
  • hemagglutination test
    Ç÷±¸ÀÀÁý½ÃÇè, Ç÷±¸ÀÀÁý°Ë»ç
  • HPV test
    (¢¡human papilloma virus test) »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • human papilloma virus test
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ, ÀúÁö¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦¿µ¿ª
  • irreversible inhibition
    ºÒ°¡¿ªÀúÁö
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ¿¬Á¢ÈľïÁ¦, ½Ã³À½ºÈľïÁ¦
  • presynaptic inhibition
    ¿¬Á¢Àü¾ïÁ¦, ½Ã³À½ºÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
  • reflex inhibition ileus
    ¹Ý»ç¾ïÁ¦Ã¢ÀÚ¸·ÈûÁõ
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • indirect inhibition
    °£Á¢¾ïÁ¦.
  • inhibition
    ¾ïÁ¦,±ÝÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦.
  • inhibition reaction
    ¾ïÁ¦(¹ÝÀÀ), ÀúÁö(¹ÝÀÀ).
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
  • inhibition, allogeneic
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tissue thromboplastin inhibition test
    Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦½ÃÇè
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • cardiac inhibition
    ½ÉÀå ¾ïÁ¦(ãýíôåäð¤)
  • cell,contact inhibition
    Á¢Ã˾ïÁ¦ (ïÈõºåäð¤)
  • chemical inhibition isoagglutinin
    È­ÇÐÀû ¾ïÁ¦ µ¿Á¾ÀÀÁý¼Ò
  • colony inhibition
    ±ÕÁý¶ô¾ïÁ¦(жó¢Õªåäð¤), ±ºÃ¼¾ïÁ¦(ÏØô÷åäð¤).
  • competitive antagonism/inhibition
    °æÀïÀû ±æÇ×/¾ïÁ¦.
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦(Ìæùêàõåäð¤).
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª).
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • conditioned inhibition
    Á¶°ÇÈ­¾ïÁ¦(ðÉËìûùåäð²)
  • contact inhibition
    Á¢ÃËÀúÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition
    "(Àû,îå)Ç÷±¸(úìϹ) ÀÀÁý ÀúÇØ(ëêó¢îÁúª)"
  • hyperbolic inhibition
    ½Ö°î¼± ÀúÇØ(äªÍØàÊîÁúª)
  • immunological inhibition
    ¸é¿ª ÀúÇØ(Øóæ¹îÁúª)
  • inhibition
    ÀúÇØ(îÁúª)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • inhibition coefficient
    ÀúÇØ°è¼ö(îÁúªÌõâ¦)
  • inhibition constant
    ÀúÇØ»ó¼ö(îÁúªßÈâ¦)
  • inhibition index
    ÀúÇØÁö¼ö(îÁúªò¦â¦)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • inhibition zone
    ÀúÇØ¿ª(îÁúªæ´)
  • linear inhibition
    ¼±ÇüÀúÇØ(àÊû¡îÁúª)
  • lysis inhibition
    ¿ëÇØÀúÇØ(éÁú°îÁúª)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
  • mixed inhibition
    È¥ÇÕÀúÇØ(ûèùêîÁúª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
  • supression test
    ¾ïÁ¦°Ë»ç
  • test
    ½ÃÇè, °Ë»ç(¹ý)
  • test object
    ½ÃÇè´ë»ó, Ç¥½Ä¹°
  • test phantom
    Ç¥ÁØÆÒÅÒ
  • test phase
    ½ÃÇè±â
  • thymol turbidity test
    Ƽ¸ôȥʽÃÇè
  • thyroid function test
    °©»ó¼±±â´É°Ë»ç
  • tolerance test
    ³»¿ë·Â°Ë»ç, ³»¿ë¼º°Ë»ç, ³»¼º°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CAT California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr...
TAT tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex...
HIT hemagglutination inhibition test; heparin-induced thrombocytopenia; histamine inhalation test; hyper...
PIT pacing-induced tachycardia; patella inhibition test; picture identification test; pitocin; pitressin...
Bz-Ty-PABA test N-Benzoyl-L-Tyrosyl-p-Amino-Benzoic Acid test
  = Bentiromide test
  = Tr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HAI haemagglutination inhibition test
E test Epsilometer test
ACEi Angiotensin I converting enzyme inhibition
BIS Behavioral Inhibition System
CEI Converting enzyme inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • negative feedback inhibition
    À½¼º µÇ¸ÔÀ̱⠾ïÁ¦
  • noncompetitive inhibition
    ºñ°æÇÕÀû ÀúÇØ
  • postsynaptic inhibition
    ½Ã³³½º ÈÄ ¾ïÁ¦
  • segmented inhibition
    ºÐÀýµÈ ¹æÇØ
  • self inhibition
    Àڱ⠾ïÁ¦
  • tonic inhibition
    ±äÀ强 ¾ïÁ¦
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
  • acetest tablet test
    ¾Æ¼¼Å×½ºÆ® Á¤ ½ÃÇè
    ¹éÁö À§¿¡ ¿Ã·Á³õÀº ¾Æ¼¼Å×½ºÆ® Á¤¿¡ ¿ä ÇÑ ¹æ¿ïÀ» ¶³¾î¶ß¸± ¶§, ¾î´À Á¤µµÀÇ ¾Æ¼¼ÅæÀÌ Á¸ÀçÇÏ¸é ±× ¾ç¿¡ µû¶ó¼­ ¾Æ¼¼Å×½ºÆ® Á¤ÀÌ ´ãÀÚ»ö
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • achievement test
    ¼öµæ´É·Â °Ë»ç, ¼öµæ´É·Âµµ °Ë»ç
  • acid elution test
    »ê ¿ë¸® ½ÃÇè
    ÅÂ¾Æ Çì¸ð±Û·ÎºóÀÇ °ËÃâ ½ÃÇèÀ¸·Î, ½½¶óÀÌµå ±Û¶ó½º À§¿¡ °ø±â °ÇÁ¶µÈ Ç÷¾× µµÆ÷ Ç¥º»À» 80% ¸ÞŸ³î·Î °íÁ¤ÇÏ¿©,
  • acoustic reflex test
    û°¢¹Ý»ç ½ÃÇè
    û°¢¹Ý»ç ¿ªÄ¡ÀÇ ÃøÁ¤¹ýÀ¸·Î¼­ Àüµµ¼º°ú °¨°¢½Å°æ¼º ³­Ã»À» °¨º° Áø´ÜÇϰųª û½Å°æÁ¾À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÈ´Ù.
  • ACTH stimulation test
    ACTH ÀÚ±Ø °Ë»ç
    Çϼöü ºÎ½ÅÇÇÁú°è ¿¹ºñ·Â°Ë»çÀÇ Çϳª. ºÎ½ÅÇÇÁúÀÚ±Ø È£¸£¸ó
  • Addis test
    ¾Æµð½º ½ÃÇè
    12½Ã°£ µ¿¾È ¿äÀÇ ÀÏÁ¤·® Áß ÀûÇ÷±¸ ¼ö, ¹éÇ÷±¸ ¼ö, »óÇǼ¼Æ÷, ¿øÁÖ, ´Ü¹é ÇÔ·®ÀÇ ÃøÁ¤. ½ÅÀå ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ »ç¿ëµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
contact inhibition of movement Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell.
(18 Nov 1997)
contact inhibition of phagocytosis Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles.
(18 Nov 1997)
haemagglutination inhibition A variation of the haemagglutination technique. Some viral antigens, when coated on erythrocytes, spontaneously cause agglutination in the absence of antibody. In these situations, the specific antigen-antibody reaction actually prevents the agglutination of reagent RBCs. Haemagglutination inhibition cannot differentiate between isotypes of specific antibodies (IgG, IgA or IgM) although positive haemagglutination inhibition analysis of specimens treated with Staphylococcus aureus Protein A (discussed above under coagglutination) to remove the IgG isotype antibodies has been used to imply the presence of specific IgM antibodies to the specific viral antigen. The crude quantitation of the specific antibodies is possible using serial dilution (titre).
(05 Mar 2000)
haemagglutination inhibition tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination.
(12 Dec 1998)
potassium inhibition Arrest of the heart in the fully relaxed state as a result of potassium intoxication.
(05 Mar 2000)
haptenic inhibition <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
hapten inhibition of precipitation Inhibition of precipitation that occurs when the precipitin has combined with hapten of the same specificity as the subsequently added antigen.
(05 Mar 2000)
proactive inhibition The state or process hypothesised to account for poorer learning rate for elements later in a series as compared to the learning rate for elements coming earlier in a series.
(12 Dec 1998)
product inhibition Inhibition of an enzyme activity by a product of the reaction catalyzed by that enzyme.
(05 Mar 2000)
selective inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
noncompetitive inhibition <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction.
(09 Oct 1997)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
nonreciprocal contact inhibition <cell biology> Collision behaviour between different cell types in which one cell shows contact inhibition of locomotion and the other does not. An example is the interaction between sarcoma cells and fibroblasts (the former not being inhibited).
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
  • herd test
    ¼Ò¶¼ÀÇ °Ë»ç(ƯÁ¤ Á¥¼Ò¶¼ÀÇ À¯Áö¹æ ÇÔÀ¯À² °Ë»ç)
  • inkblot test
    RORSCHACH TEST
  • intelligence test
    ±â´É°Ë»ç
  • intradermal test
    (ÀÇ)Çdz»(¸é¿ª)Å×½ºÆ®
  • mantoux test
    ¸ÁÅõ ¹ÝÀÀ (°áÇÙÀ̳ª °¨¿°ÀÇ °Ë»ç¿ë)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á